Skip navigation

Vistara Single-Gene NIPT

Vistara is the most comprehensive prenatal single-gene screening test for serious genetic conditions. These conditions, which affect quality of life, could benefit from early intervention and might otherwise go undetected.

Vistara tests for 25 serious genetic conditions with a blood draw from the mother. Most results will be returned to a clinician within 2-3 weeks.

Vistara, single-gene NIPT, enables deeper insights for better health outcomes

Vistara is the next evolution in NIPT

Early insights guide healthier futures

  • Screen for 25 autosomal dominant and X-linked conditions across 30 genes with Vistara single-gene NIPT
    • Combined incidence greater than Down syndrome1,2
  • Provide clinically actionable information
    • Many single-gene conditions benefit from early intervention
    • Inform decisions for pregnancy and delivery management, early interventions, and patient education to ensure every child reaches their full potential
  • Perform testing with ease and get clear results
    • No paternal and/or egg-donor* sample necessary
    • Find conditions other screening modalities would miss until after the window for critical intervention

*if applicable

Vistara Chart Incidence at Birth

Vistara screens conditions with a combined incidence greater than Down syndrome

See list of conditions

All pregnancies can benefit from Vistara

Some scenarios where single-gene NIPT should be considered


Couples with a male partner over 40-years-old (advanced paternal age)


Ultrasound anomalies including shortened long bones and increased nuchal translucency


Family history of hereditary conditions


Patients who want as much information as possible

With only one blood-draw from the mother required, ordering Vistara is simple and can be integrated into any office scenario

only one blood-draw from the mother required

No errors detected in clinical validation

Vistara’s clinical validation published in Nature Medicine (Zhang et al) showed the following performance metrics:2

  • >99% sensitivity
  • >99% specificity


Make confident pregnancy management and early intervention decisions with performance you can trust

Vistara is a screening test, which means that Vistara does not make a final diagnosis. A screen-positive Vistara result means that a pregnancy could be affected by the condition that has screened positive. However, it cannot be known for sure if a baby has that condition based upon screening results alone. All medical decisions should be made after discussion with a heathcare provider regarding diagnostic testing during the pregnancy, like amniocentesis or chorionic villus sampling (CVS), or testing the baby after delivery.

Vistara is an incomparable adjunct to traditional diagnostic procedures like chorionic villus sampling (CVS) and amniocentesis with:

  • One of the most comprehensive Noonan panels available
  • Screening for conditions not included in standard diagnostic microarray


Findings on Vistara can be confirmed using the same original diagnostic sample, no need for additional confirmatory procedures**


**Cells must be saved for additional diagnostic testing

Vistara Chart Incidence at Birth

Is Vistara right for you?

We’re here to help you find out

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.


1Snijders, et al. Ultrasound Obstet Gynecol 1999;13:167-170.

2Zhang J et al. Nat Med. 2019 Mar;25(3):439-447.

3Pagon RA et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017.

icon-angle icon-bars icon-times